Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sucampo Pharma Applies for Amitiza in Japan
October 18, 2010
- DSP Launches Lonasen through Bukwang in South Korea
October 18, 2010
- Kapvay Approved for AD/HD in the US: Shionogi
October 18, 2010
- Otsuka Sets Up SalesSubsidiary in Canada
October 18, 2010
- Tasigna Recommended for EU Approval as 1st-Line Treatment for CML
October 18, 2010
- FDA Extends Review Period for Avastin for Advanced Breast Cancer
October 11, 2010
- Abraxan Makes Outpatients' Life Easier: Taiho
October 11, 2010
- Zeria, Astellas Apply for Acotiamide in Japan
October 11, 2010
- Astellas Aims at Overseas Vaccines Market
October 11, 2010
- Revolade Recommended for Approval
October 11, 2010
- ASKA, Senju Create Ceolia Pharma
October 11, 2010
- Fingolimod Approved in the US: Novartis
October 11, 2010
- CMIC Licenses Ecallantide for HAE from Dyax
October 11, 2010
- Gov't, Industry to Discuss How to Ensure Stable Supply of Molybdenum
October 11, 2010
- Panelists Call For Support of Ventures: BioJapan 2010
October 11, 2010
- L-FABP Testing Agent Approved: CMIC
October 11, 2010
- Mediceo to Build Cost-Conscious Company: President Watanabe
October 11, 2010
- Roche to Seek More Alliance Opportunities to Develop Innovative Drugs
October 11, 2010
- New Premium Should Not Affect Price Negotiations: Yonbyokyo
October 11, 2010
- Eisai Ties Up with Anaeropharma to Develop Anticancer Agents
October 11, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…